| US Status | Dietary Supplement (OTC) |
|---|---|
| EU Status | Novel Food considerations |
| FDA Drug | NOT approved |
| CAS Number | 14605-22-2 |
| China Classification | Pharma Intermediate / Supplement |
| Japan Classification | Health Food / Functional Ingredient |
| India Classification | Pharma API |
| Regulatory Framework (US) | DSHEA 1994 |
TUDCA's regulatory status is one of the more confusing topics in the supplement and pharmaceutical raw material trade because it differs by country and by intended use. This guide explains how TUDCA is classified in each major market as of July 2026, what documentation buyers need for import, and where the regulatory risks lie.
In the United States, TUDCA is sold as an over-the-counter dietary supplement. This classification falls under the Dietary Supplement Health and Education Act of 1994 (DSHEA), which permits substances with a history of use as dietary supplements before 1994 -- or substances that are constituents of food -- to be marketed without FDA drug approval. TUDCA qualifies because it is a natural constituent of human bile, present at low concentrations as the taurine conjugate of ursodeoxycholic acid.
TUDCA is not FDA-approved as a drug for any medical condition. This is a frequent point of confusion. TUDCA's parent compound, UDCA (ursodeoxycholic acid), is FDA-approved as a prescription drug (brand names URSO 250, URSO Forte, Actigall) for primary biliary cholangitis and for gallstone dissolution. TUDCA itself has no FDA drug approval. The Phase 3 TUDCA-ALS trial completed in 2024 did not meet its primary endpoint, making near-term FDA drug approval unlikely.
The FDA has issued warning letters to supplement companies making disease treatment claims for TUDCA. Under DSHEA, supplements may bear structure/function claims (e.g., "supports liver health") but may not claim to treat, prevent, or cure any disease (e.g., "treats ALS," "prevents Alzheimer's"). Companies importing TUDCA for the US supplement market should review product labeling and marketing claims against FDA enforcement patterns to avoid regulatory exposure.
For raw material import, TUDCA does not require FDA pre-market notification. However, the manufacturer must register with the FDA as a food facility under the Bioterrorism Act, and the product must comply with current Good Manufacturing Practice (cGMP) regulations for dietary supplements (21 CFR Part 111). A Drug Master File (DMF) is not required for supplement-grade import but may be requested by US-based formulators who want to reference the supplier's quality data in their own regulatory filings.
The EU presents the most complex regulatory picture for TUDCA. Under Regulation (EU) 2015/2283, any food or food ingredient not consumed to a significant degree in the EU before May 15, 1997, is classified as a novel food and requires pre-market authorization from the European Food Safety Authority (EFSA) before it can be legally placed on the market. TUDCA, as a synthetic bile acid derivative, was almost certainly not consumed as a food or food supplement in the EU before 1997, and it is not listed on the EU's Union List of authorized novel foods. This places TUDCA in a regulatory gray zone.
Country-by-country variation within the EU. While the novel food regulation is EU-wide, enforcement varies by member state. Germany (DE) has generally taken a permissive approach to supplement ingredients not explicitly prohibited, and TUDCA supplements have been available through German online retailers and pharmacies. The Netherlands (NL) similarly allows many supplement ingredients unless specifically restricted. The UK, post-Brexit, now operates its own novel food regime under the Food Standards Agency (FSA), which largely mirrors the EU framework but operates independently -- TUDCA's status in the UK should be verified through the FSA's novel foods list.
For businesses considering importing TUDCA into the EU as a supplement ingredient, the legally conservative approach is to submit a novel food authorization application -- a process that typically takes 9-24 months and requires a full safety dossier. A faster alternative is to seek an Article 4 consultation (under Implementing Regulation 2018/456) with a competent national authority to obtain an official determination of whether TUDCA is novel in that member state. Some businesses operate in the regulatory gray zone, importing TUDCA as a research chemical or pharmaceutical intermediate (not for human consumption as a food), though this approach carries its own risks if the product enters the consumer supply chain.
In China, TUDCA produced under GMP conditions is regulated as a pharmaceutical intermediate or API by the National Medical Products Administration (NMPA). Chinese manufacturers producing pharmaceutical-grade TUDCA must hold valid pharmaceutical production licenses and comply with Chinese GMP standards aligned with ICH Q7. The domestic TUDCA supplement market in China is growing, with products sold through cross-border e-commerce channels and domestic health food stores, but the primary regulatory identity of TUDCA in China is pharmaceutical.
For export, the classification depends on the intended use declared by the buyer. TUDCA exported as a pharmaceutical intermediate requires GMP documentation, batch-specific CoA, and sometimes a DMF reference or Certificate of Suitability (CEP) if destined for the EU market. TUDCA exported as a supplement ingredient may follow a lighter documentation path, though quality documentation (CoA, MSDS, heavy metals report) is still standard.
Japan's Foods with Function Claims (FFC) system, established in 2015, provides a regulatory pathway for ingredients like TUDCA to be marketed with specific health claims. Under this system, businesses submit scientific evidence to the Consumer Affairs Agency supporting their proposed claim, and upon acceptance, the product can be sold with the approved functional claim. TUDCA has a path as a health food ingredient in Japan, and several Japanese supplement brands have launched TUDCA-containing products. The regulatory burden is lower than pharmaceutical registration but higher than the US DSHEA framework, as health claims must be supported by submitted evidence.
In India, TUDCA is regulated as a pharmaceutical API under the Drugs and Cosmetics Act. Import requires registration with the Central Drugs Standard Control Organization (CDSCO), and the importing entity must hold a valid manufacturing or import license. India's pharmaceutical regulatory framework is more restrictive for supplement ingredients than the US model, and TUDCA intended for the Indian market typically moves through pharmaceutical rather than nutraceutical channels. Indian formulators importing TUDCA API for finished dosage form production must comply with Schedule M (GMP requirements) and provide the standard API documentation package: DMF, CoA, stability data, and certificate of pharmaceutical product (CPP) if available.
Brazil -- ANVISA. Brazil's National Health Surveillance Agency (ANVISA) classifies TUDCA based on its intended use and dosage form. As a pharmaceutical raw material, TUDCA falls under ANVISA's API registration requirements. For supplement applications, Brazil's regulatory framework for "novos alimentos e novos ingredientes" (new foods and new ingredients) under RDC 240/2018 and related resolutions requires safety demonstration before market access. TUDCA does not appear on ANVISA's list of approved supplement ingredients as of 2026, meaning a registration process would be required for supplement marketing. Import of pharmaceutical-grade TUDCA for manufacturing purposes follows ANVISA's API import procedures, including Good Manufacturing Practices certification of the foreign manufacturer.
Mexico -- COFEPRIS. Mexico's Federal Commission for Protection against Sanitary Risk (COFEPRIS) regulates TUDCA under its pharmaceutical and supplement frameworks depending on the product classification. The regulatory pathway for importing TUDCA as a supplement ingredient requires registration as a "suplemento alimenticio" (food supplement), with documentation including a certificate of free sale from the country of origin, CoA, and manufacturing license. COFEPRIS enforcement has intensified since 2023, and importers should verify current requirements directly with the agency or through a Mexican regulatory consultant before shipping.
Importing TUDCA across borders requires attention to three layers of documentation: customs clearance, product-specific regulatory compliance, and buyer requirements.
Customs documentation typically includes the commercial invoice, packing list, bill of lading or airway bill, certificate of origin, and the HS code classification. TUDCA's HS code is generally under 2924.29 (cyclic amides), though exact classification can vary by country and should be confirmed with a customs broker. Incorrect HS code classification can cause customs delays, additional duties, or seizure.
Product-specific documentation varies by the importing country's regulatory classification. For the US supplement market, a certificate of analysis (CoA) and GMP certificate are typically sufficient. For EU pharmaceutical import, a CEP or DMF reference and Certificate of GMP Compliance are standard. For markets where TUDCA is pharmaceutical-only (India, much of Latin America), the full pharmaceutical API documentation package applies: DMF, CoA, stability data, GMP certificate, and potentially a CPP.
Buyer requirements often exceed regulatory minimums. Many formulators and distributors require documentation beyond what customs requires, including: heavy metals testing (USP <231> or equivalent), residual solvents statement (ICH Q3C), microbiological testing results, allergen statement, BSE/TSE statement (relevant for bovine bile-derived products), and a third-party lab CoA for verification. Suppliers who can provide this documentation package without repeated requests save buyers time and reduce supply chain friction.